TuHURA Biosciences (HURA) Price & Analysis

Compare

988 Followers

HURA Stock Chart & Stats

$1.24

-$0.03(-0.55%)

At close: Jan 08 4:00 PM EST

$1.24

-$0.03(-0.55%)

Day’s Range― - ―

52-Week Range$0.41 - $4.44

Previous CloseN/A

Volume116.05K

Average Volume (3M)215.15K

Market Cap

$85.01M

Enterprise Value$76.95M

Total Cash (Recent Filing)$2.70M

Total Debt (Recent Filing)$577.73K

Price to Earnings (P/E)―

Beta0.89

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding60,720,510

10 Day Avg. Volume212,396

30 Day Avg. Volume215,145

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)5.23

Price to Sales (P/S)0.00

P/FCF Ratio-5.16

Enterprise Value/Market Cap0.91

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.43K

Enterprise Value/Ebitda-2.68

Forecast

1Y Price Target

$9.00

Price Target Upside625.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Combination PotentialPreliminary signals for IFx-2.0 combined with Keytruda in anti‑PD1–refractory melanoma could broaden the treatable patient population and increase the drug's commercial opportunity if replicated in later trials.

Upcoming Clinical ReadoutsInterim AML data for an anti‑VISTA antibody plus a menin inhibitor and Phase 3 top‑line results in Merkel cell carcinoma represent distinct value inflection points that could materially re‑rate the pipeline.

Valuation And Market PositioningA pronounced share‑price decline alongside a biotech sector reset can create an attractive entry point and upside potential if upcoming clinical milestones are achieved and financing access remains available.

Bears Say

Clinical And Competitive RiskNegative clinical results, development delays, or stronger competing checkpoint inhibitors could significantly diminish expected commercial prospects and investor confidence.

Financing And Dilution RiskPlanned financings and reliance on at‑the‑market offerings may increase dilution risk and put downward pressure on the stock despite providing near‑term capital for execution.

Regulatory UncertaintyOrphan Drug Designation that does not match the Phase 3 trial indication introduces ambiguity around regulatory strategy and could limit the practical benefit of the designation.

TuHURA Biosciences News

TuHURA Biosciences files INDA for TBS-2025 in blood-related cancers

TuHURA Biosciences (HURA) has filed an Investigational New Drug Application, or INDA, with the FDA’s Division of Hematologic...

8d ago

HURA

VOO vs. VTI vs. VTWO: Which Vanguard ETF Offers the Best Upside in 2026?

With markets shifting and investors looking ahead to 2026, choosing the right Vanguard ETF could make a big...

17d ago

VOO

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/6/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 1.40% in...

19d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/4/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.28% in...

21d ago

IMA

TuHURA Biosciences says FDA grants Orphan Drug Designation to IFx-2.0

TuHURA Biosciences (HURA) announced that the U.S FDA Office of Orphan Products Development has granted Orphan Drug Designation...

23d ago

HURA

TuHURA Biosciences: Undervalued Orphan-Drug Oncology Pipeline with Multiple Near-Term Catalysts Supports Reiterated Buy and $10 Target

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on TuHURA Biosciences, retaining the price target of...

22d ago

HURA

TuHURA Biosciences Receives Nasdaq Minimum Bid Price Notice

The latest update is out from TuHURA Biosciences ( ($HURA) ). On January 29, 2026, TuHURA Biosciences disclosed...

26d ago

HURA

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on TuHURA Biosciences (HURA) to $10 from $12...

2M ago

HURA

TuHURA Biosciences announces release of Kintara’s CVR

TuHURA Biosciences (HURA) announced that Kintara’s REM-001 clinical trial of ten metastatic cutaneous breast cancer patients met its...

2M ago

HURA

TuHURA Biosciences provides updates across portfolio

TuHURA Biosciences (HURA) provided updates across the company’s portfolio of assets, including a summary from its mini symposium...

3M ago

HURA

TuHURA Biosciences Announces Securities Purchase Agreement

TuHURA Biosciences ( ($HURA) ) has provided an announcement. On December 9, 2025, TuHURA Biosciences announced a securities...

3M ago

HURA

TuHURA Biosciences announces $15.6M registered direct offering

TuHURA Biosciences (HURA) announced that it has entered into a definitive agreement for the purchase of an aggregate...

3M ago

HURA

TuHURA Biosciences presents research on potential role of DOR at ASH

TuHURA Biosciences (HURA) announced that its research on the potential role of the Delta Opioid Receptor in controlling...

3M ago

HURA

TuHURA Biosciences Amends Loan Agreement, Secures Full $3M

The latest update is out from TuHURA Biosciences ( ($HURA) ). TuHURA Biosciences, Inc. entered into a Secured...

3M ago

HURA

HURA FAQ

What was TuHURA Biosciences’s price range in the past 12 months?

TuHURA Biosciences lowest stock price was $0.41 and its highest was $4.44 in the past 12 months.

What is TuHURA Biosciences’s market cap?

TuHURA Biosciences’s market cap is $85.01M.

When is TuHURA Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were TuHURA Biosciences’s earnings last quarter?

Currently, no data Available

Is TuHURA Biosciences overvalued?

According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TuHURA Biosciences pay dividends?

TuHURA Biosciences does not currently pay dividends.

What is TuHURA Biosciences’s EPS estimate?

TuHURA Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TuHURA Biosciences have?

TuHURA Biosciences has 60,720,510 shares outstanding.

What happened to TuHURA Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of TuHURA Biosciences?

Currently, no hedge funds are holding shares in HURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

TuHURA Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-418.06%

Trailing 12-Months

Asset Growth

1736.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TuHURA Biosciences

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

TuHURA Biosciences (HURA) Earnings & Revenues

Historic Earnings Reports

HURA Stock 12 Month Forecast

Average Price Target

$9.00

▲(625.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"136":"$136","-1":"-$1","33.25":"$33.3","67.5":"$67.5","101.75":"$101.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,33.25,67.5,101.75,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.518,1.2473846153846153,1.9767692307692306,2.706153846153846,3.435538461538461,4.164923076923077,4.894307692307692,5.623692307692306,6.353076923076922,7.082461538461538,7.811846153846153,8.541230769230769,9.270615384615384,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.518,1.1704615384615384,1.8229230769230769,2.4753846153846153,3.1278461538461535,3.7803076923076917,4.432769230769231,5.085230769230769,5.737692307692307,6.390153846153845,7.042615384615384,7.695076923076923,8.347538461538461,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.518,1.0935384615384616,1.6690769230769231,2.2446153846153845,2.820153846153846,3.3956923076923076,3.971230769230769,4.546769230769231,5.122307692307692,5.697846153846154,6.273384615384615,6.848923076923077,7.4244615384615384,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":135.625,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.756,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.518,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >